Pharma

Your Article Summary

See Latest Articles

Responses After Completion of Therapy Increase Pixantrone CR/CRu Rate to 24% and ORR to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial
Cell Therapeutics, 06/23/09

Cell Therapeutics, Inc. announced that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09

Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09

See All of Drug Trials